First dose of misoprostol administration at home or in hospital for medical abortion between 12–22 gestational weeks in Sweden (PRIMA): a multicentre, open-label, randomised controlled trial.

MLA

Rydelius, Johanna, et al. “First Dose of Misoprostol Administration at Home or in Hospital for Medical Abortion between 12–22 Gestational Weeks in Sweden (PRIMA): A Multicentre, Open-Label, Randomised Controlled Trial.” Lancet, vol. 404, no. 10455, Aug. 2024, pp. 864–73. EBSCOhost, https://doi.org/10.1016/S0140-6736(24)01079-1.

APA

Rydelius, J., Hognert, H., Kopp-Kallner, H., Brandell, K., Romell, J., Zetterström, K., Teleman, P., & Gemzell-Danielsson, K. (2024). First dose of misoprostol administration at home or in hospital for medical abortion between 12–22 gestational weeks in Sweden (PRIMA): a multicentre, open-label, randomised controlled trial. Lancet, 404(10455), 864–873. https://doi.org/10.1016/S0140-6736(24)01079-1

Chicago

Rydelius, Johanna, Helena Hognert, Helena Kopp-Kallner, Karin Brandell, Joanna Romell, Karin Zetterström, Pia Teleman, and Kristina Gemzell-Danielsson. 2024. “First Dose of Misoprostol Administration at Home or in Hospital for Medical Abortion between 12–22 Gestational Weeks in Sweden (PRIMA): A Multicentre, Open-Label, Randomised Controlled Trial.” Lancet 404 (10455): 864–73. doi:10.1016/S0140-6736(24)01079-1.